|Bid||1.67 x 1800|
|Ask||1.68 x 4000|
|Day's Range||1.67 - 1.77|
|52 Week Range||0.98 - 6.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
WESTLAKE VILLAGE, Calif., Sept. 13, 2018-- MannKind Corporation announced today that "Improved Postprandial Glucose with Inhaled Technosphere ® Insulin Compared to Insulin Aspart in Patients with ...
NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. On September 4th, MannKind announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. MNKD doubled its market share over the past year as a result of its commercialization efforts and are excited about its new Afrezza clinical data being released throughout 2018.
A new cash lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker Amarin.
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
After spending much of 2017 in a downtrend, MannKind (NASDAQ:MNKD) lit up on the stock market and closed above $2.00 a share on Sept. 4 for the first time since June. The company announced that it would collaborate with United Therapeutics (NASDAQ:UTHR) on treprostinil, an investigational drug for the treatment of pulmonary arterial hypertension. The cash infusion from the deal is just what MannKind needed.
MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.
Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.
United Therapeutics and MannKind’s collaboration is for an investigational treprostinil dry powder that is presently in clinical trials. According to the terms of the agreement, United Therapeutics (UTHR) is responsible for the development, regulatory activities, and commercialization of this dry powder.
The good news for MNKD stock comes in the form of an agreement to have it manufacture a dry powder formulation of treprostinil. This is a drug that is currently in testing for treating pulmonary arterial hypertension. The deal will have MannKind acting as the manufacturer for clinical supplies of the drug and its initial commercial run. For its efforts, the company is getting an upfront payment of $45 million.
CORAL GABLES, FL / ACCESSWIRE / September 4, 2018 / Health care stocks have made a sharp swing to the upside so far in the third quarter, leading the some of the major markets like the S&P 500. "Overall they look quite good," stated Matt Maley, equity strategist at Miller Tabak, in an interview with CNBC. Thehealth care ETF (XLV), he adds, has "been making a nice series of higher highs and higher lows." During this same period, a number of bigger companies are using their large cash positions to targetsmall cap biotech companies through strategic investments and setting sights on new acquisitions.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Nike Inc (NYSE: NKE ) stock was trading lower by nearly ...
Under the deal with MannKind Corp., Silver Spring's United Therapeutics will be responsible for global development, regulatory and commercial activities for the dry power formulation and inhalation delivery of treprostinil, the active ingredient in United Therapeutics' flagship product Remodulin.
WESTLAKE VILLAGE, Calif., Aug. 29, 2018-- MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and ...
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind ...
Beauty product retailer Natural Health Trends Corp. of Rolling Hills was the Los Angeles-area's biggest gainer, rising from 23 cents on March 9, 2009 to $25.90 on Aug. 21 of this year, an increase of 11,160 percent.
The second-quarter earnings season has produced plenty of shockers, and pharmaceutical company MannKind (NASDAQ:MNKD) is one of them. After posting a disastrous miss on the top-line, and financial metrics that implied a viability concern, MNKD stock tanked more than 23%. In the year-ago quarter, MannKind posted a 35-cent EPS loss.